Puriblood Medical Co., Ltd. (TPEX:6847)
Taiwan · Delayed Price · Currency is TWD 88.70
+0.60 (0.68%)
Jun 3, 2026, 1:52 PM CST
Puriblood Medical Revenue
In the year 2025, Puriblood Medical had annual revenue of 82.34M TWD, down -25.61%. Puriblood Medical had revenue of 40.25M in the half year ending June 30, 2025, with 24.67% growth.
Revenue
82.34M
Revenue Growth
-25.61%
P/S Ratio
15.33
Revenue / Employee
1.87M
Employees
44
Market Cap
1.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 82.34M | -28.34M | -25.61% |
| Dec 31, 2024 | 110.67M | -14.60M | -11.65% |
| Dec 31, 2023 | 125.27M | -12.17M | -8.86% |
| Dec 31, 2022 | 137.44M | 82.86M | 151.79% |
| Dec 31, 2021 | 54.59M | 15.94M | 41.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIONET | 1.26B |
| DIVA Laboratories | 884.63M |
| Genetics Generation Advancement | 609.13M |
| Kim Forest Enterprise | 549.14M |
| Sofiva Genomics | 382.82M |
| Welgene Biotech | 381.82M |
| Pharmigene | 199.89M |